Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
Bristol-Myers Squibb
BMYHealthcareGenerated Jul 5, 2026, 08:12 PM UTC
BMY (Bristol-Myers Squibb) analytical snapshot. Revenue declined +2.5% YoY to $45.01B. Net margin at 17.83% (expanding ▲). Return on equity 49.13%, ROA 8.67%, ROIC 0.00%. Market cap $118.71B at $58.13 per share. Trailing P/E 15.06, P/S 2.64, P/B 5.92. Graham number $29.21 (trades above intrinsic). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score 12 (data confidence 83%). Descriptive analytics from public filings — not investment advice.
Market cap
$118.71B
2.04B shares
Price
$58.13
NYQ
P/E (ttm)
15.06
Revenue (FY)
$45.01B
YoY -2.5%
Net margin
17.83%
▲ 39.03pp
Free cash flow
$12.65B
28.11% margin
Risk level
Elevated
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score 10Stable
80% conf
Revenue declined +2.5% YoY to $45.01B. Net margin at 17.83% (expanding ▲). Return on equity 49.13%, ROA 8.67%, ROIC 0.00%.
- Revenue declined +2.5% YoY to $45.01B.
- Net margin at 17.83% (expanding ▲).
- Return on equity 49.13%, ROA 8.67%, ROIC 0.00%.
- Gross margin 0.00%, operating margin 0.00%.
- Free cash flow margin 28.11% ($12.65B).
- Net income up ▲ +26.8% YoY.
- Debt/equity 2.20, current ratio 1.42, net debt $34.57B.
- Asset turnover 0.52 — capital efficiency.
Revenue (FY)
$45.01B
YoY -2.5%
Net margin
17.83%
▲ 39.03pp
ROE
49.13%
ROA 8.67%
ROIC
0.00%
EPS (diluted)
$3.86
FY2025
Free cash flow
$12.65B
28.11% margin
Debt / equity
2.20
Cash $9.57B
Current ratio
1.42
Equity $20.07B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | — | — | — | — | — | $2.62B | 14.05 |
| 2017 | — | — | — | — | — | $1.28B | 9.67 |
| 2018 | $19.43B | — | 18.86 | 0.00 | 22.94 | $1.84B | 37.96 |
| 2019 | $20.78B | +6.9% | 17.47 | 0.00 | 4.85 | $4.22B | 7.18 |
| 2020 | $22.56B | +8.6% | 18.16 | 0.00 | 21.81 | $6.12B | 9.54 |
| 2021 | $26.14B | +15.9% | 0.00 | 0.00 | 13.15 | $7.37B | 9.09 |
| 2022 | $42.52B | +62.6% | 0.00 | 0.00 | -21.20 | $13.30B | -25.08 |
| 2023 | $46.38B | +9.1% | 0.00 | 0.00 | 15.08 | $15.23B | 22.52 |
| 2024 | $46.16B | -0.5% | 0.00 | 0.00 | 13.71 | $11.95B | 21.50 |
| 2025 | $45.01B | -2.5% | 0.00 | 0.00 | 17.83 | $12.65B | 49.13 |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 31, 2025 | $11.20B | -5.6% | — | 21.93% |
| Jun 30, 2025 | $23.47B | -2.5% | +109.5% | 16.05% |
| Jun 30, 2025 | $12.27B | -49.0% | -47.7% | 30.70% |
| Sep 30, 2025 | $35.69B | -0.7% | +190.9% | 16.72% |
| Sep 30, 2025 | $12.22B | -66.0% | -65.8% | 48.82% |
| Mar 31, 2026 | $11.49B | +2.6% | -6.0% | 23.30% |
Revenue (annual, SEC 10-K)
2016: 0
2017: 0
2018: 19,427
2019: 20,776
2020: 22,561
2021: 26,145
2022: 42,518
2023: 46,385
2024: 46,159
2025: 45,006
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Profitability trends (%)
GrossOperatingNet
Free cash flow (annual)
2016: 2,622
2017: 1,285
2018: 1,843
2019: 4,220
2020: 6,115
2021: 7,374
2022: 13,299
2023: 15,234
2024: 11,948
2025: 12,651
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 30Improving
80% conf
Latest annual report (10-K) filed Feb 11, 2026. Latest quarterly report (10-Q) filed Apr 30, 2026. 11 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 11, 2026.
- Latest quarterly report (10-Q) filed Apr 30, 2026.
- 11 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Bristol-Myers Squibb; broad institutional reporting.
- Recent filers include SUMMIT SECURITIES GROUP, LLC, CLEAR STREET MARKETS LLC, FREMONT INVESTMENT ADVISORS INC.
- 14 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 6 recent 13G passive institutional ownership notices.
Latest 10-K
Feb 11, 2026
Annual report
Latest 10-Q
Apr 30, 2026
8-K (recent)
11
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
14
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| SUMMIT SECURITIES GROUP, LLC | 13F-HR | May 9, 2019 |
| CLEAR STREET MARKETS LLC | 13F-HR | Apr 28, 2020 |
| FREMONT INVESTMENT ADVISORS INC | 13F-HR | Oct 22, 2001 |
| FREMONT INVESTMENT ADVISORS INC | 13F-HR | Jan 16, 2002 |
| Axiom Investment Management LLC | 13F-HR | Mar 16, 2021 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| May 8, 2026 | 8-K | CURRENT REPORT |
| Apr 30, 2026 | 8-K | 8-K |
| Feb 5, 2026 | 8-K | 8-K |
| Jan 12, 2026 | 8-K | CURRENT REPORT |
| Nov 18, 2025 | 8-K | CURRENT REPORT |
| Nov 10, 2025 | 8-K | FORM 8-K |
| Nov 3, 2025 | 8-K | CURRENT REPORT |
| Oct 30, 2025 | 8-K | 8-K |
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -57Deteriorating
70% conf
4 risk signal(s), 1 positive signal(s) detected from XBRL filing diff analysis. The combination of explicit "going concern" language in the filing with deteriorating cash flow or rising leverage is a severe warning signal — the company's own auditors have flagged doubt about the ability to continue as a going concern.
- Leverage is building — debt rising while equity contracts: Long-term debt grew +25.1% while stockholders equity declined -44.5%. The debt-to-equity ratio is deteriorating, increasing financial risk and interest burden. This may constrain future borrowing capacity.
- NEW: Going concern doubt in latest filing: The term "going concern" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 6 filing(s).
- Material weakness in internal controls: The term "material weakness" appears in 19 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 15 filing(s).
- Operating cash flow exceeds net income: OCF is 1.73x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Endogenous analysis: The combination of explicit "going concern" language in the filing with deteriorating cash flow or rising leverage is a severe warning signal — the company's own auditors have flagged doubt about the ability to continue as a going concern.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 2 new risk-language term(s) detected in filing text: Going concern doubt, Restatement of financial statements.
- Ongoing high-severity risk language: Material weakness in internal controls.
Revenue
$45.01B
-2.5% YoY
Gross profit
$4.10B
+12.9% YoY
Net income
$8.03B
+26.8% YoY
Operating cash flow
$13.86B
+6.1% YoY
Capex
$1.21B
+8.1% YoY
Total assets
$92.60B
-2.7% YoY
Total liabilities
$76.22B
+16.1% YoY
Long-term debt
$49.43B
+25.1% YoY
Filing quality score
65/100
stable
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $46.16B | $45.01B | $-1.15B | -2.5% |
| Gross profit | $3.63B | $4.10B | $467.0M | +12.9% |
| Net income | $6.33B | $8.03B | $1.70B | +26.8% |
| Operating cash flow | $13.07B | $13.86B | $794.0M | +6.1% |
| Capex | $1.12B | $1.21B | $91.0M | +8.1% |
| Total assets | $95.16B | $92.60B | $-2.56B | -2.7% |
| Total liabilities | $65.67B | $76.22B | $10.54B | +16.1% |
| Long-term debt | $39.53B | $49.43B | $9.90B | +25.1% |
| Cash & equivalents | $11.46B | $10.35B | $-1.12B | -9.8% |
| Stockholders equity | $29.43B | $16.34B | $-13.10B | -44.5% |
| Inventory | $2.66B | $2.56B | $-105.0M | -3.9% |
| Accounts receivable | $8.88B | $9.01B | $130.0M | +1.5% |
| R&D expense | $9.51B | $9.30B | $-210.0M | -2.2% |
| SG&A expense | $7.81B | $7.77B | $-42.0M | -0.5% |
| Interest expense | $1.42B | $1.33B | $-86.0M | -6.1% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Removed | BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1, CommonStockParOrStatedValuePerShare, CommonStockSharesAuthorized, CommonStockSharesIssued, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentIncomeTaxExpenseBenefit, DebtInstrumentCarryingAmount, DeferredFederalIncomeTaxExpenseBenefit, DeferredForeignIncomeTaxExpenseBenefit |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Going concern doubt | high | 6 | 0 | NEW |
| Material weakness in internal controls | high | 19 | 2 | Ongoing |
| Restatement of financial statements | high | 15 | 0 | NEW |
| Impairment charge | medium | 78 | 7 | Ongoing |
| Restructuring | medium | 249 | 22 | Ongoing |
| Off-balance sheet arrangements | medium | 11 | 2 | Ongoing |
| Related party transactions | low | 13 | 2 | Ongoing |
Filing signal breakdown
Red flags: 4
Positive: 1
Watch: 0
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $118.71B at $58.13 per share.
- ProPrice & TechnicalsPrice $58.13 — uptrend (above 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Elevated.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite 12
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Bristol-Myers Squibb is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewMarket cap $118.71B at $58.13 per share..
Risk
Elevated
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow BMY stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY● you | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |
| Thermo Fisher Scientific TMO | — | Neutral |
| Vertex Pharmaceuticals VRTX | — | Neutral |
| Gilead Sciences GILD | — | Neutral |
| Zoetis Inc. ZTS | — | Neutral |
| Kimberly-Clark Corp. KMB | — | Neutral |
| Hershey Co. HSY | — | Neutral |
| Sysco Corp. SYY | — | Neutral |
| Moderna Inc. MRNA | — | Neutral |
| Biogen Inc. BIIB | — | Neutral |
| DexCom Inc. DXCM | — | Neutral |